Compare Stocks: BNR, CMPX, PRTC, and LRMR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$9.22 -2.4%	$9.56	$6.79 ▼ $41.72	$99.40M	1.38	7,359 shs	3,387 shs
CMPX Compass Therapeutics	$2.31 -3.3%	$2.20	$1.61 ▼ $6.88	$430.41M	0.95	3.21 million shs	1.51 million shs
LRMR Larimar Therapeutics	$3.94 +3.1%	$3.88	$2.71 ▼ $6.42	$396.83M	0.74	1.06 million shs	755,347 shs
PRTC PureTech Health	$17.42	$17.42	$14.50 ▼ $19.92	$424.04M	1.15	18,480 shs	N/A

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	-2.43%	-6.67%	+4.89%	+4.62%	+7.79%
CMPX Compass Therapeutics	-3.35%	-8.70%	+20.94%	+10.00%	-33.81%
LRMR Larimar Therapeutics	+3.14%	-5.29%	+3.14%	+23.13%	+8.84%
PRTC PureTech Health	0.00%	0.00%	0.00%	0.00%	+2.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$9.22 -2.4%	$9.56	$6.79 ▼ $41.72	$99.40M	1.38	7,359 shs	3,387 shs
CMPX Compass Therapeutics	$2.31 -3.3%	$2.20	$1.61 ▼ $6.88	$430.41M	0.95	3.21 million shs	1.51 million shs
LRMR Larimar Therapeutics	$3.94 +3.1%	$3.88	$2.71 ▼ $6.42	$396.83M	0.74	1.06 million shs	755,347 shs
PRTC PureTech Health	$17.42	$17.42	$14.50 ▼ $19.92	$424.04M	1.15	18,480 shs	N/A

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	-2.43%	-6.67%	+4.89%	+4.62%	+7.79%
CMPX Compass Therapeutics	-3.35%	-8.70%	+20.94%	+10.00%	-33.81%
LRMR Larimar Therapeutics	+3.14%	-5.29%	+3.14%	+23.13%	+8.84%
PRTC PureTech Health	0.00%	0.00%	0.00%	0.00%	+2.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNR Burning Rock Biotech	1.00	Sell	N/A	N/A
CMPX Compass Therapeutics	2.88	Moderate Buy	$11.77	409.49% Upside
LRMR Larimar Therapeutics	3.10	Buy	$11.67	196.11% Upside
PRTC PureTech Health	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BNR, CMPX, PRTC, and LRMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	CMPX Compass Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
8/5/2026	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$12.00 ➝ $11.00
7/31/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CMPX Compass Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	LRMR Larimar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/2/2026	LRMR Larimar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
7/1/2026	CMPX Compass Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$5.00
6/30/2026	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNR Burning Rock Biotech	$77.16M	1.26	N/A	N/A	$7.28 per share	1.27
CMPX Compass Therapeutics	$850K	489.42	N/A	N/A	$0.92 per share	2.51
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$1.23 per share	N/A
PRTC PureTech Health	$4.66M	91.01	N/A	N/A	$12.65 per share	1.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNR Burning Rock Biotech	-$7.92M	-$0.82	N/A	N/A	N/A	-11.57%	-10.98%	-7.33%	9/2/2026 (Estimated)
CMPX Compass Therapeutics	-$66.49M	-$0.40	N/A	N/A	N/A	N/A	-38.71%	-34.72%	11/4/2026 (Estimated)
LRMR Larimar Therapeutics	-$165.67M	-$1.95	N/A	N/A	N/A	N/A	-137.39%	-97.65%	11/5/2026 (Estimated)
PRTC PureTech Health	-$109.74M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest BNR, CMPX, PRTC, and LRMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	Q2 2026	BNR Burning Rock Biotech	-$2.2883	N/A	N/A	N/A	$19.21 million	N/A
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A
8/4/2026	Q2 2026	LRMR Larimar Therapeutics	-$0.3815	-$0.30	+$0.0815	-$0.30	N/A	N/A
6/9/2026	Q1 2026	BNR Burning Rock Biotech	-$2.2884	-$0.20	+$2.0884	-$0.25	$19.21 million	$15.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNR Burning Rock Biotech	0.06	3.05	2.81
CMPX Compass Therapeutics	N/A	11.22	11.22
LRMR Larimar Therapeutics	N/A	4.70	4.70
PRTC PureTech Health	N/A	6.59	6.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNR Burning Rock Biotech	30.03%
CMPX Compass Therapeutics	68.43%
LRMR Larimar Therapeutics	91.92%
PRTC PureTech Health	0.04%

Insider Ownership

Company	Insider Ownership
BNR Burning Rock Biotech	30.30%
CMPX Compass Therapeutics	18.70%
LRMR Larimar Therapeutics	4.00%
PRTC PureTech Health	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNR Burning Rock Biotech	1,390	10.52 million	7.33 million	Not Optionable
CMPX Compass Therapeutics	20	180.09 million	146.41 million	Not Optionable
LRMR Larimar Therapeutics	30	103.88 million	99.73 million	Optionable
PRTC PureTech Health	100	24.34 million	23.05 million	Not Optionable

BNR, CMPX, PRTC, and LRMR Headlines

Recent News About These Companies

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis ...

July 13, 2026 | finance.yahoo.com

PureTech Subsidiary Celea Begins Phase 3 IPF Study Comparing Deupirfenidone With Standard Therapy (PRTC)

July 13, 2026 | uk.finance.yahoo.com

PureTech entity Celea raises $180 million to move lung disease drug into late stage trial

July 2, 2026 | reuters.com

PureTech Health plc American Depositary Shares (PRTC) Real-Time

July 1, 2026 | nasdaq.com

2 UK shares tipped to more than double my money in 2026!

June 20, 2026 | uk.finance.yahoo.com

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

June 9, 2026 | finance.yahoo.com

PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference

May 13, 2026 | businesswire.com

PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO

May 1, 2026 | proactiveinvestors.co.uk

PureTech Announces Annual Results for Year Ended December 31, 2025

April 29, 2026 | businesswire.com

PureTech Health: Notice of Results

April 13, 2026 | businesswire.com

PureTech Gains on Results

April 2, 2026 | baystreet.ca

PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine

April 2, 2026 | businesswire.com

PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans

March 25, 2026 | businesswire.com

PureTech to Present at the Leerink Partners Global Healthcare Conference

February 25, 2026 | businesswire.com

PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

February 19, 2026 | businesswire.com

PureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

January 14, 2026 | seekingalpha.com

PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference

January 6, 2026 | finance.yahoo.com

PureTech CEO to present at JP Morgan Healthcare Conference

January 6, 2026 | msn.com

PureTech Health plc (LON:PRTC) is favoured by institutional owners who hold 73% of the company

January 3, 2026 | finance.yahoo.com

PureTech Appoints Robert Lyne as Chief Executive Officer

December 18, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR, CMPX, PRTC, and LRMR Company Descriptions

Burning Rock Biotech NASDAQ:BNR

$9.22 -0.23 (-2.43%)

As of 09/1/2026 03:00 PM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Compass Therapeutics NASDAQ:CMPX

$2.31 -0.08 (-3.35%)

As of 09/1/2026 04:00 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Larimar Therapeutics NASDAQ:LRMR

$3.94 +0.12 (+3.14%)

As of 09/1/2026 04:00 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

PureTech Health NASDAQ:PRTC

$17.42 0.00 (0.00%)

As of 08/31/2026

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNR, CMPX, PRTC, and LRMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNR, CMPX, PRTC, and LRMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNR, CMPX, PRTC, and LRMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR, CMPX, PRTC, and LRMR Company Descriptions

Burning Rock Biotech NASDAQ:BNR

Compass Therapeutics NASDAQ:CMPX

Larimar Therapeutics NASDAQ:LRMR

PureTech Health NASDAQ:PRTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNR, CMPX, PRTC, and LRMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNR, CMPX, PRTC, and LRMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNR, CMPX, PRTC, and LRMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR, CMPX, PRTC, and LRMR Company Descriptions

Burning Rock Biotech NASDAQ:BNR

Compass Therapeutics NASDAQ:CMPX

Larimar Therapeutics NASDAQ:LRMR

PureTech Health NASDAQ:PRTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools